Table 2. Heart functional recovery parameters by E2 and in presence of MEK1/2, PKC translocation and PI-3K inhibitors in WT mice.
| Groups | LVSP (mmHg) | LVEDP(mmHg) | LVDP(mmHg) | HR(min) | Time |
|---|---|---|---|---|---|
| Control | 97±5 | 4±1 | 93±5 | 176±9 | Basal |
| E2 | 100±6 | 2±2 | 97±3 | 169±8 | |
| E2+U0126 | 106±5 | 7±3 | 99±2 | 166±15 | |
| E2+LY294002 | 109±12 | 8±1 | 101±12 | 153±12 | |
| E2+CC | 92±12 | 2±1 | 90±13 | 210±21 | |
| Control | 37±3 | 9±2 | 28±2 | 167±17 | 20 min |
| E2 | 65±4 * | 2.5±2 | 63±4 * | 160±8 | |
| E2+U0126 | 57±9 | 16±5 | 39±9 # | 194±21 | |
| E2+LY294002 | 67±4 | 8±1 | 59±4 | 139±19 | |
| E2+CC | 37±7 + | 12±8 | 25±3 + | 220±37 | |
| Control | 45±3 | 9±2 | 36±2 | 167±15 | 40 min |
| E2 | 71±2 * | 3±1 | 68±2 * | 173±6 | |
| E2+U0126 | 66±14 | 23±17 | 43±7 # | 200±22 | |
| E2+LY294002 | 81±17 | 8±1 | 73±16 | 175±39 | |
| E2+CC | 45±21 + | 13±9 | 33±5 + | 211±29 | |
| Control | 43±2 | 9±2 | 34±2 | 179±14 | 60 min |
| E2 | 71±5 * | 3±2 | 68±2 * | 168±4 | |
| E2+U0126 | 72±11 | 22±16 | 49±6 # | 180±34 | |
| E2+LY294002 | 81±10 | 10±3 | 71±8 | 188±16 | |
| E2+CC | 50±12 + | 13±1 | 37±5 + | 160±9 |
Cardiac functional parameters in WT male mice. Left ventricular systolic pressure (LVSP); left ventricular end-diastolic pressure (LVEDP); left ventricular developed pressure (LVDP) and heart rate (HR) before ischemia (Basal) and at different times of reperfusion after I/R in control, E2-treated, and E2+Inhibitors (U0126, LY294002 and CC: chelerythrine chloride). Values are mean±SEM.
* P<0.05 control versus E2 group (n = 6-7/ group)
+ P<0.05 E2+CC versus E2 group (n = 4-6/ group)
# P<0.05 E2+U0126 versus E2 group (n = 4–6 hearts/ group)